I
ISA Pharmaceuticals
Developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections
About ISA Pharmaceuticals
ISA Pharmaceuticals focuses on developing targeted, rationally designed immunotherapeutics for the treatment of cancer and persistent virus infections. The company operates in the biotechnology sector, primarily serving patients and healthcare providers. ISA Pharmaceuticals' business model revolves around the research, development, and commercialization of immunotherapy treatments. Revenue is generated through the sale of these treatments, as well as potential partnerships and licensing agreements with other pharmaceutical companies. The company is actively involved in clinical trials, such as the Phase II combination trial of its lead immunotherapy ISA101b. ISA Pharmaceuticals also adapts to emerging health crises, as evidenced by its development of ISA106 SLP therapeutic for COVID-19.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jul 2021 | $29M | $114M | Invest-NL · Regeneron Pharmaceuticals | — |
| DEBT✓Debt | Oct 2019 | $22M | — | European Investment Bank | — |
Growth signals
Latest recorded traffic for ISA Pharmaceuticals is 610 monthly website visits, up 5.2% over the last three months. ISA Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
ISA Pharmaceuticals in the Leiden ecosystem
The ISA Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Invest-NL
Regeneron Pharmaceuticals
Series B and later1 investor entered at this stage
European Investment Bank
Other known investors2 additional known investors
Aglaia BioMedical Ventures
Karl Rothweiler
Source: Dealroom Talent Intelligence.
Global footprint
See ISA Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








